Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind’s Proprietary MEAI Compound
Ryan Allway November 18th, 2021 Psychedelics Professor Gal Yadid, renowned neuropsychopharmacologist, to spearhead the project Toronto, Ontario–(Newsfile Corp. – November 18, 2021) – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )